Ovid Therapeutics announces Phase 1 clearance for OV4071

The Company will initiate a Phase 1 trial for OV4071, a potential first-in-class, oral, direct activator of potassium-chloride cotransporter 2 following Human Research Ethics Committee approval of the Phase 1 study and Clinical Trial Notification acknowledgement from the Australian Therapeutic Goods Administration.